Edge Therapeutics (NASDAQ:EDGE) announced its quarterly earnings data on Thursday. The biotechnology company reported ($0.11) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.27) by $0.16, MarketWatch Earnings reports.
Shares of NASDAQ:EDGE opened at $0.70 on Friday. Edge Therapeutics has a 12-month low of $0.68 and a 12-month high of $17.77.
Separately, ValuEngine raised Edge Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday. One research analyst has rated the stock with a sell rating, two have issued a hold rating and two have given a buy rating to the stock. The stock presently has an average rating of “Hold” and an average target price of $14.50.
Edge Therapeutics, Inc, a clinical-stage biotechnology company, discovers, develops, and seeks to commercialize hospital-based therapies for acute life-threatening neurological and other conditions. Its lead product includes EG-1962, a polymer-based microparticle used for the treatment of aneurysmal subarachnoid hemorrhage.
Further Reading: Market Capitalization – What it Means for Investors
Receive News & Ratings for Edge Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edge Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.